In pyroluria, a metabolic byproduct called kryptopyrrole binds to zinc and B6 and carries them out in the urine. The result is a persistent functional deficiency of two of the most critical cofactors in neurotransmitter synthesis, stress response, and immune function — regardless of dietary intake or standard supplementation.
Pyroluria — also called kryptopyroluria (KPU) or the mauve factor — is a metabolic condition in which the body produces excess hydroxyhemopyrrolin-2-one (HPL), commonly known as kryptopyrroles. These are byproducts of haemoglobin synthesis that, in normal amounts, are excreted harmlessly. In pyroluria, they are produced in excess and have an important chemical property: they bind avidly to zinc and to pyridoxine (B6), and carry both out of the body in the urine.
The result is not a dietary deficiency. It is a metabolic drain. No matter how much zinc and B6 a pyroluric individual consumes through food or standard supplementation, the kryptopyrroles continue to bind and excrete these nutrients. The deficiency is continuous and progressive unless the specific mechanism is identified and addressed with the appropriate forms and doses.
B6 (as P5P — pyridoxal-5-phosphate): Required as a cofactor for glutamate decarboxylase (GAD) — the enzyme that converts glutamate to GABA. Low B6 = impaired GABA synthesis = insufficient inhibitory neurotransmitter = anxiety, hyperexcitability, seizure susceptibility. Also required for serotonin synthesis (AADC enzyme), dopamine synthesis, and all transamination reactions. B6 insufficiency functionally impairs every major neurotransmitter pathway simultaneously.
Zinc: Required for over 300 enzymatic reactions. In the context of neurobiology: zinc modulates NMDA glutamate receptors (excess glutamate → anxiety, OCD, excitotoxicity), supports GABA-A receptor function, is essential for thymic function and T-cell development (immune), wound healing, collagen synthesis, and reproductive hormone function. Low zinc in pyroluria creates a neurotransmitter and immune deficit simultaneously.
The vicious cycle: Low B6 → impaired GABA synthesis → elevated glutamate → anxiety and hyperexcitability → stress response activation → increased kryptopyrrole production → further B6 and zinc loss. Stress worsens pyroluria; pyroluria worsens stress response. Standard anxiolytic treatment addresses the anxiety without touching the mechanism.
Pyroluria has a characteristic clinical picture that, when present as a cluster, is strongly suggestive of the condition. No single symptom is diagnostic in isolation — the pattern matters. Estimated prevalence: approximately 10–15% of the general population, rising to 30–40% in people with anxiety disorders, ADHD, autism spectrum conditions, OCD, and schizophrenia.
The classic pyroluric profile: severe anxiety that doesn’t respond well to standard treatment, white spots on fingernails, stretch marks, no dream recall, poor morning appetite, and a history of reading difficulties or neurodevelopmental differences in childhood. Not every feature needs to be present — but when several cluster together, this is worth testing.
Low B6 impairs GAD (glutamate→GABA conversion), maintaining the glutamate excess and GABA insufficiency that drives OCD hyperactivation of CSTC circuits. NAC and magnesium address glutamate — but if B6 insufficiency from pyroluria is present, GABA synthesis remains impaired regardless.
Pyroluria prevalence of 30–40% in ADHD is consistent with the dopamine and noradrenaline synthesis dependence on B6. Low zinc impairs NMDA receptor modulation, contributing to the hyperexcitability and impulsivity of ADHD presentations.
Pyroluria and MTHFR variants commonly co-occur and compound each other. MTHFR impairs folate and B12 cycling; pyroluria depletes zinc and B6. Together they create a comprehensive nutrient deficit underlying treatment-resistant mood and neurological presentations.
Zinc is essential for thymic function and T-cell development. Chronic zinc depletion through pyroluria impairs cell-mediated immunity — the same arm responsible for viral surveillance (relevant to recurrent shingles, recurrent infections, and slow wound healing).
Amino acid precursor protocols (5-HTP for serotonin, tyrosine for dopamine) will underperform if B6 is depleted by pyroluria — B6 is the cofactor for every decarboxylase step in neurotransmitter synthesis. Pyroluria is the plug-out-of-the-bath problem that makes repletion ineffective.
Stress increases kryptopyrrole production, worsening pyroluria. Pyroluria worsens stress response by impairing GABA and depleting zinc (adrenal function). DUTCH will often show dysregulated cortisol patterns in pyroluric clients — the HPA dysfunction is partly a consequence of the nutrient deficit.
Pyroluria is assessed via a kryptopyrrole urine test, also called the mauve factor test. It is a simple urine collection but requires careful handling — kryptopyrroles are photosensitive and degrade rapidly on exposure to light and heat. Improper sample handling is the most common cause of false negative results.
Sample: First morning urine, collected in a light-protected (dark or foil-wrapped) container. The sample should be frozen within 30 minutes of collection and shipped on ice to the laboratory. Do not leave at room temperature.
Reference ranges: <10 µg/dL = normal. 10–20 µg/dL = borderline elevated, clinically significant in context. >20 µg/dL = positive pyroluria. >30 µg/dL = significantly elevated. Some labs use different units (mmol/mol creatinine) — always check which reference range applies to the result you receive.
Important note: A negative result does not definitively exclude pyroluria if sample handling was suboptimal or if the client was recently under unusually low stress. Repeat testing under standardised conditions if clinical suspicion remains high despite a low result.
Cost: Approximately £50–80 depending on the laboratory. Available via Mosaic Diagnostics (formerly Great Plains Laboratory) and specialist functional labs.
Treatment for pyroluria involves high-dose zinc and B6 (as P5P — not plain pyridoxine, as many pyroluric individuals have impaired B6→P5P conversion). Starting doses that are too high cause nausea, copper displacement, and paradoxical worsening of symptoms. The correct approach is a gradual titration over weeks, not an immediate high-dose protocol. This is a supervised clinical intervention, not a self-management supplement programme. If you have a positive result, please discuss the treatment protocol in a consultation before beginning supplementation.
Kryptopyrrole testing can be added to any programme as an advanced investigation — particularly relevant alongside Neurogistics neurotransmitter assessment, DUTCH, Metabolomix+ OAT, and methylation testing. Ask the DH Concierge whether this test makes sense for your specific presentation, or book a free 20-minute call to discuss.
Ask the Concierge → Book a free 20-minute call